Betamethasone benzoate
CAS: 22298-29-9
Ref. 3D-FB178826
1g | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued | ||
250mg | Discontinued | ||
500mg | Discontinued |
Product Information
- (11Beta,16Beta)-9-Fluoro-11,21-Dihydroxy-16-Methyl-3,20-Dioxopregna-1,4-Dien-17-Yl Benzoate
- (11β,16β)-17-(Benzoyloxy)-9-fluoro-11,21-dihydroxy-16-methylpregna-1,4-diene-3,20-dione
- (8Xi,10Xi,11Beta,13Xi,16Beta)-9-Fluoro-11,21-Dihydroxy-16-Methyl-3,20-Dioxopregna-1,4-Dien-17-Yl Benzoate
- Bebate
- Beben
- Benisone
- Betamethasone Benzoate
- Euvaderm
- Flurobate
- Ms 1112
- See more synonyms
- Parbetan
- Pregna-1,4-diene-3,20-dione, 17-(benzoyloxy)-9-fluoro-11,21-dihydroxy-16-methyl-, (11β,16β)-
- Pregna-1,4-diene-3,20-dione, 9-fluoro-11β,17,21-trihydroxy-16β-methyl-, 17-benzoate
- Uticort
- W 5975
Betamethasone benzoate is a steroid that belongs to the group of corticosteroids. The biological properties of betamethasone benzoate are similar to those of other corticosteroids. This drug is used for the treatment and prevention of inflammatory skin diseases, such as psoriasis and eczema, or for the treatment of allergies. Betamethasone benzoate has shown anti-inflammatory activities in heart tissue and has been shown to be safe at doses up to 4 mg/kg in toxicity studies. The drug also had no significant effects on metal hydroxides or fatty acid metabolism in rats. In addition, this drug showed no evidence of carcinogenic activity in mice after oral administration.